Zyla Life Sciences, a commercial-stage life sciences company, reported financial results for the first quarter ended March 31, 2020, including net sales from commercial products: SPRIX® Nasal Spray, the SoluMatrix® products, VIVLODEX® and ZORVOLEX® ), INDOCIN® suppositories, INDOCIN® oral suspension and OXAYDO® tablets for oral use only –CII.
May 15, 2020
· 14 min read